Advertisement

Patients with HFpEF and HFmrEF have different clinical characteristics in Turkey: A multicenter observational study

Published:November 13, 2018DOI:https://doi.org/10.1016/j.ejim.2018.11.001

      Highlights

      • Clinical profile and pathophysiology of HFmrEF and HFpEF are heterogeneous.
      • Basic characteristics and etiology of HFmrEF are significantly different from HFpEF.
      • HFmrEF and HFpEF is now occurring increasingly in younger age groups.
      • HFmrEF and HFpEF treated less aggressively in Turkey compared with western countries.

      Abstract

      Background

      To determine and compare the demographic characteristics, clinical profile and management of patients with heart failure with mid-range ejection fraction (HFmrEF) and heart failure with preserved ejection fraction (HFpEF) in a Turkish cohort.

      Methods

      The APOLLON trial (A comPrehensive, ObservationaL registry of heart faiLure with mid-range and preserved ejection fractiON) is an observational and multicenter study conducted in Turkey. Consecutive patients admitted to the cardiology clinics who were at least 18 years of age and had HFmrEF or HFpEF were included (NCT03026114).

      Results

      The study population included 1065 (mean age of 67.1 ± 10.6 years, 54% women) patients from 12 sites in Turkey. Among participants, 246 (23.1%) had HFmrEF and 819 (76.9%) had HFpEF. Compared to patients with HFpEF, those with HFmrEF were more likely to be male (57.7 vs 42.2%; p < 0.001), had higher N-terminal pro-B-type natriuretic peptide levels (853 vs 528 pg/ml, p < 0.001), were more likely to have ECG abnormalities (72.4 vs 53.5%, p < 0.001) and hospitalization history for heart failure (28 vs 18.6%; p = 0.002). HFmrEF patients were more likely to use β-blockers (69.9 vs 55.2%, p < 0.001), aldosterone receptor antagonists (24 vs 14.7%, p = 0.001), statins (37 vs 23%, p < .001), and loop diuretics (39.8 vs 30.5%, p = 0.006) compared to patients with HFpEF.

      Conclusions

      The results of APOLLON study support that the basic characteristics and etiology of HFmrEF are significantly different from HFpEF. This registry also showed that the patients with HFmrEF and HFpEF were younger but undertreated in Turkey compared to patients in western countries.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Yancy C.W.
        • Jessup M.
        • Bozkurt B.
        • Butler J.
        • Casey Jr., D.E.
        • Drazner M.H.
        • et al.
        2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.
        Circulation. 2013 Oct 15; 128: 1810-1852
        • Borlaug B.A.
        • Redfield M.M.
        Diastolic and systolic heart failure are distinct phenotypes within the heart failure spectrum.
        Circulation. 2011 May 10; 123 ([discussion 2014]): 2006-2013
        • JJ McMurray
        • Adamopoulos S.
        • Anker S.D.
        • Auricchio A.
        • Böhm M.
        • Dickstein K.
        • et al.
        The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart failure Association (HFA) of the ESC.
        Eur Heart J. 2012; 33: 1787-1847
        • Ponikowski P.
        • Voors A.A.
        • Anker S.D.
        • Bueno H.
        • Cleland J.G.F.
        • Coats A.J.S.
        • et al.
        ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)developed with the special contribution of the Heart FailureAssociation (HFA) of the ESC.
        Eur Heart J. 2016; 37: 2129-2200
        • Tribouilloy C.
        • Rusinaru D.
        • Mahjoub H.
        • Soulière V.
        • Lévy F.
        • Peltier M.
        • et al.
        Prognosis of heart failure with preserved ejection fraction: a 5 year prospective population-based study.
        Eur Heart J. 2008 Feb; 29: 339-347
        • Farré N.
        • Lupon J.
        • Roig E.
        • Gonzalez-Costello J.
        • Vila J.
        • Perez S.
        • et al.
        Clinical characteristics, one-year change in ejection fraction and long-term outcomes in patients with heart failure with mid-range ejection fraction: a multicentre prospective observational study in Catalonia (Spain).
        BMJ Open. 2017 Dec 21; 7e018719
        • Özlek B.
        • Özlek E.
        • Çelik O.
        • Çil C.
        • Doğan V.
        • Tekinalp M.
        • et al.
        Rationale, Design, and Methodology of the APOLLON trial: a comPrehensive, ObservationaL registry of heart faiLure with midrange and preserved ejectiON fraction.
        Anatol J Cardiol. 2018 May; 19: 311-318
        • Levey A.S.
        • Bosch J.P.
        • Lewis J.B.
        • Greene T.
        • Rogers N.
        • Roth D.
        A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.
        Ann Intern Med. 1999 Mar 16; 130: 461-470
        • Oktay A.A.
        • Rich J.D.
        • Shah S.J.
        The emerging epidemic of heart failure with preserved ejection fraction.
        Curr Heart Fail Rep. 2013 Dec; 10: 401-410
        • Georgiopoulou V.V.
        • Velayati A.
        • Burkman G.
        • Li S.
        • Farooq K.
        • Samman-Tahhan A.
        • et al.
        Comorbidities, sociodemographic factors, and hospitalizations in outpatients with heart failure and preserved ejection fraction.
        Am J Cardiol. 2018 May 15; 121: 1207-1213
        • Lee D.S.
        • Gona P.
        • Vasan R.S.
        • Larson M.G.
        • Benjamin E.J.
        • Wang T.J.
        • et al.
        Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the Framingham heart study of the national heart, lung, and blood institute.
        Circulation. 2009 Jun 23; 119: 3070-3077
        • Shah S.J.
        • Heitner J.F.
        • Sweitzer N.K.
        • Anand I.S.
        • Kim H.Y.
        • Harty B.
        • et al.
        Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial.
        Circ Heart Fail. 2013 Mar; 6: 184-192
        • Tribouilloy C.
        • Rusinaru D.
        • Mahjoub H.
        • Soulière V.
        • Lévy F.
        • Peltier M.
        • et al.
        Prognosis of heart failure with preserved ejection fraction: a 5 year prospective population-based study.
        Eur Heart J. 2008 Feb; 29: 339-347
        • Owan T.E.
        • Hodge D.O.
        • Herges R.M.
        • Jacobsen S.J.
        • Roger V.L.
        • Redfield M.M.
        Trends in prevalence and outcome of heart failure with preserved ejection fraction.
        N Engl J Med. 2006 Jul 20; 355: 251-259
        • Kapoor J.R.
        • Kapoor R.
        • Ju C.
        • Heidenreich P.A.
        • Eapen Z.J.
        • Hernandez A.F.
        • et al.
        Precipitating clinical factors, heart failure characterization, and outcomes in patients hospitalized with heart failure with reduced, borderline, and preserved ejection fraction.
        JACC Heart Fail. 2016 Jun; 4: 464-472
        • Lauritsen J.
        • Gustafsson F.
        • Abdulla J.
        Characteristics and long-term prognosis of patients with heart failure and mid-range ejection fraction compared with reduced and preserved ejection fraction: a systematic review and meta-analysis.
        ESC Heart Fail. 2018 Apr 16; https://doi.org/10.1002/ehf2.12283
        • Cheng R.K.
        • Cox M.
        • Neely M.L.
        • Heidenreich P.A.
        • Bhatt D.L.
        • Eapen Z.J.
        • et al.
        Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population.
        Am Heart J. 2014 Nov; 168: 721-730
        • Nauta J.F.
        • Hummel Y.M.
        • van Melle J.P.
        • van der Meer P.
        • Lam C.S.P.
        • Ponikowski P.
        • et al.
        What have we learned about heart failure with mid-range ejection fraction one year after its introduction?.
        Eur J Heart Fail. 2017 Dec; 19: 1569-1573
        • Crespo-Leiro M.G.
        • Anker S.D.
        • Maggioni A.P.
        • Coats A.J.
        • Filippatos G.
        • Ruschitzka F.
        • et al.
        Heart failure Association (HFA) of the European Society of Cardiology (ESC). European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions.
        Eur J Heart Fail. 2016 Jun; 18: 613-625
        • Rickenbacher P.
        • Kaufmann B.A.
        • Maeder M.T.
        • Bernheim A.
        • Goetschalckx K.
        • Pfister O.
        • et al.
        Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the Trial of Intensified versus standard Medical therapy in elderly patients with Congestive Heart failure (TIME-CHF).
        Eur J Heart Fail. 2017 Dec; 19: 1586-1596
        • Sartipy U.
        • Dahlström U.
        • Fu M.
        • Lund L.H.
        Atrial fibrillation in heart failure with preserved, mid-range, and reduced ejection fraction.
        JACC Heart Fail. 2017 Aug; 5: 565-574
        • Abebe T.B.
        • Gebreyohannes E.A.
        • Tefera Y.G.
        • Abegaz T.M.
        Patients with HFpEF and HFrEF have different clinical characteristics but similar prognosis: a retrospective cohort study.
        BMC Cardiovasc Disord. 2016 Nov 21; 16: 232
        • Hamatani Y.
        • Nagai T.
        • Shiraishi Y.
        • Kohsaka S.
        • Nakai M.
        • Nishimura K.
        • et al.
        Investigators for the WET-NaDEF Collaboration Project. Long-Term Prognostic significance of Plasma B-Type Natriuretic Peptide Level in patients with Acute Heart failure with Reduced, Mid-Range, and Preserved Ejection Fractions.
        Am J Cardiol. 2018 Mar 15; 121: 731-738
        • Tromp J.
        • Khan M.A.
        • Klip I.T1.
        • Meyer S.
        • de Boer R.A.
        • Jaarsma T.
        • et al.
        Biomarker profiles in heart failure patients with preserved and reduced ejection fraction.
        J Am Heart Assoc. 2017 Mar 30; 6: e003989https://doi.org/10.1161/JAHA.116.003989
        • Koenig W.
        • Sund M.
        • Fröhlich M.
        • Fischer H.G.
        • Löwel H.
        • Döring A.
        • et al.
        C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992.
        Circulation. 1999 Jan 19; 99: 237-242
        • Koh A.S.
        • Tay W.T.
        • Teng T.H.K.
        • Vedin O.
        • Benson L.
        • Dahlstrom U.
        • et al.
        A comprehensive population-based characterization of heart failure with mid-range ejection fraction.
        Eur J Heart Fail. 2017 Dec; 19: 1624-1634
        • Hsu J.J.
        • Ziaeian B.
        • Fonarow G.C.
        Heart failure with Mid-Range (Borderline) Ejection Fraction.
        Clin Impl Future Direct JACC Heart Fail. 2017 Nov; 5: 763-771
        • Fonarow G.C.
        • Stough W.G.
        • Abraham W.T.
        • Albert N.M.
        • Gheorghiade M.
        • Greenberg B.H.
        • et al.
        OPTIMIZE-HF investigators and hospitals. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry.
        J Am Coll Cardiol. 2007 Aug 21; 50: 768-777
        • Nativi-Nicolau J.
        • Ryan J.J.
        • Fang J.C.
        Current therapeutic approach in heart failure with preserved ejection fraction.
        Heart Fail Clin. 2014 Jul; 10: 525-538
        • Komajda M.
        • Lam C.S.
        Heart failure with preserved ejection fraction: a clinical dilemma.
        Eur Heart J. 2014 Apr; 35: 1022-1032